JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harden, R. N.
Right arrow Articles by Gracely, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harden, R. N.
Right arrow Articles by Gracely, R. H.
Related Collections
Right arrow Pain
Right arrow Pharmacology

Anesth Analg 2004;99:1478-1485
© 2004 International Anesthesia Research Society
doi: 10.1213/01.ANE.0000132549.25154.ED

PAIN MEDICINE

Increased Systemic Catecholamines in Complex Regional Pain Syndrome and Relationship to Psychological Factors: A Pilot Study

R. Norman Harden, MD*,{dagger},{ddagger}, Nathan J. Rudin, MA MD§, Stephen Bruehl, PhD||, William Kee, PhD, Devang K. Parikh, MS#, Jason Kooch, MD{dagger}, Thomas Duc, MD, and Richard H. Gracely, PhD**

*Center for Pain Studies, Chicago, Illinois; {dagger} Rehabilitation Institute of Chicago, Chicago, Illinois; {ddagger} Northwestern University Medical School, Chicago, Illinois; § Department of Orthopedics and Rehabilitation Medicine and Pain Treatment and Research Center, University of Wisconsin Medical School, Madison, Wisconsin; ||Vanderbilt University School of Medicine, Nashville, Tennessee; ¶Medical University of South Carolina, Charleston, South Carolina; #University of Pennsylvania, Philadelphia, Pennsylvania; and **Chronic Pain and Fatigue Research Program, University of Michigan Health System, Ann Arbor, Michigan

Address correspondence and reprint requests to R. Norman Harden, MD, Rehabilitation Institute of Chicago, Center For Pain Studies, 446 E. Ontario, Ste. 1011, Chicago, IL 60611. Address e-mail to nharden{at}rehabchicago.org


   Abstract
Top
 Abstract
Introduction
 Methods
 Results
 Discussion
 References
 
We have demonstrated that subjects with complex regional pain syndrome (CRPS) have asymmetric venous pool plasma concentrations of norepinephrine (NE) when affected and unaffected limbs are compared, with most demonstrating decreased NE levels in the affected limb. This pilot study explored whether systemic venous plasma catecholamine levels in CRPS subjects with sympathetically maintained pain (SMP) differ from those found in healthy volunteers. We also explored whether catecholamine levels were correlated with scores on psychometric measures of depression, anxiety, and personality. Venous blood samples from 33 CRPS/SMP patients (from unaffected limbs) and 30 healthy control subjects were assayed for plasma NE and epinephrine (E) concentrations. Plasma NE levels were significantly higher in the CRPS group (P < 0.001). Statistical comparisons of E levels across groups did not achieve significance (P < 0.06), although 52% of CRPS/SMP patients had E levels exceeding the 95% confidence interval based on control data. Significant positive correlations were found between E levels and scores on the Beck Depression Inventory and Scales 1, 3, and 6 on the Minnesota Multiphasic Personality Inventory-2 (all P < 0.05). This preliminary work suggests that increased NE and E levels in CRPS/SMP patients may result from the pain of CRPS, consequent affective distress, or both. Alternatively, our findings could reflect premorbid adrenergic hyperactivity caused by affective, endocrine, or other pathology, which might predispose these individuals to develop the syndrome. Definitive studies are needed to examine these hypotheses in detail.

IMPLICATIONS: This pilot study explored systemic venous plasma catecholamine levels in complex regional pain syndrome and the correlation with scores on psychometric measures. Our results suggest that increased catecholamine levels may result from pain or may reflect premorbid adrenergic hyperactivity, which could predispose these individuals to develop the syndrome.


   Introduction
Top
 Abstract
 Introduction
Methods
 Results
 Discussion
 References
 
Despite considerable advances in our understanding of pain pathophysiology, complex regional pain syndrome (CRPS) (1) remains a challenging and enigmatic disorder. The processes underlying CRPS remain incompletely understood and are the focus of intense research. Numerous precipitating events, most involving physical trauma or prolonged immobilization, have been identified (2), but why only a small subset of individuals develop CRPS after common traumas remains a mystery.

CRPS is often associated with apparent dysfunction in the sympathetic nervous system; it clinically presents as dysautonomic changes (e.g., edema, increased sweating, and decreased temperature) in the affected limbs, which superficially appear to reflect a state of chronic sympathetic hyperactivity. However, sympatholytic treatments such as nerve blocks (3) and surgical sympathectomies often have incomplete or temporary effects, and a significant portion of CRPS patients do not respond to them at all. Raja et al. (4) classify these nonresponders as having sympathetically independent pain (SIP), whereas those whose symptoms improve after chemical or surgical sympatholysis have sympathetically maintained pain (SMP) (5).

If the sympathetic nervous system is not "overdriven," then the dysautonomia so prominent in chronic CRPS may suggest some form of adrenergic supersensitivity (6,7). Studies using models of peripheral nerve injury (8,9) support this concept, suggesting that tissue injury can trigger adrenosensitivity in injured afferent axons and surrounding vessels independently of sympathetic activity. Therefore, after nerve injury, circulating catecholamines may directly trigger nociceptive firing (10) and the vasomotor changes characteristic of the syndrome (6,7). Drummond et al. (11) found that CRPS patients experience more pain during states of sympathetic arousal, lending further support to this hypothesis.

We previously compared venous pool plasma catecholamine levels between affected and unaffected limbs of CRPS patients with SMP, all of whom manifested the dysautonomic changes classic in this syndrome, and we observed a small but significant decrease in venous plasma norepinephrine (NE) on the affected side (7). Drummond et al. (6) reported similar findings. Although the reasons for the decrease require further exploration, these results further contradict the hypothesis that the dysautonomia of CRPS is mediated by sympathetic hyperactivity in the affected limb. Instead, the more likely mechanism is peripheral adrenosensitivity, with circulating catecholamines causing an exaggerated peripheral autonomic response (6,7).

In this previous work, we noted that many CRPS patients had systemic plasma NE and epinephrine (E) levels in excess of prototypical normal ranges (derived from only five control subjects in that study) (7). In individuals without chronic pain, plasma NE and E levels increase during dysphoric emotional states such as anxiety, hostility, and depression (12,13) and may be reduced by relaxation techniques (14). Depression and anxiety are reported to be increased in CRPS patients (15), and these individuals’ increased systemic NE and E may be a consequence of the pain or the affective distress accompanying the syndrome. In a patient with peripheral adrenosensitivity in the affected limb, increased plasma NE and E would be expected to result in dysautonomia and, hypothetically, pain.

No study has formally compared systemic plasma catecholamine levels in CRPS patients with those in healthy controls, which is the purpose of this pilot work. CRPS patients with SMP were specifically chosen because their responsiveness to sympathetic blockade suggested direct or indirect involvement of sympathetic nervous system function in the production or maintenance of symptoms. This study also reports our preliminary investigation of interactions between psychological variables and plasma catecholamine levels with a series of standardized psychometric tests. If affective distress is positively correlated with catecholamine levels in CRPS patients and if our hypothesis that chronic CRPS subjects have peripheral adrenosensitivity is correct, then this relationship would suggest one mechanism by which psychological factors might influence the development, maintenance, and exacerbation of the syndrome.


   Methods
Top
 Abstract
 Introduction
 Methods
Results
 Discussion
 References
 
The study protocol was reviewed and approved by the Northwestern University and Medical University of South Carolina (MUSC) IRBs. All subjects provided informed consent after thorough explanation of the protocol, potential risks, and potential benefits.

Thirty-three individuals with upper limb CRPS were recruited from among the patients enrolled in the MUSC chronic pain treatment program. Each met published International Association for the Study of Pain (IASP) criteria for CRPS (1). All patients were also classified as having SMP, as indicated by at least a 50% decrease in visual analog pain ratings in response to paravertebral sympathetic ganglion blockade. All subjects were at least 1 wk out from their last block. This response to block was required for inclusion in the data set, with the assumption that this defined a more homogeneous group than the IASP diagnostic criteria alone—a group that was responsive to gross sympathetic manipulation and therefore exemplary of the hypothesis. The study was not designed to assess the effect of sympathetic blockade on pain, affect, or catecholamine levels. Twenty-three patients were subjects in our previous catecholamine investigation (7). In this pilot study, no attempt was made to control for medications.

Control subjects were 30 healthy volunteers who were recruited from the faculty and support staff of MUSC and the Rehabilitation Institute of Chicago. Criteria for inclusion as a control were 1) absence of any major physical or psychiatric disorder (by bedside history/assessment); 2) no regular psychoactive, endocrine, or antihypertensive medication (diuretics were permissible); 3) no known allergy or sensitivity to heparin; 4) age between 18 and 70 yr; 5) no history of exaggerated bleeding tendency or thrombocytopenia; and 6) ability to provide informed consent. Efforts were made to match ages of patients and control subjects, but these attempts were limited by control subject availability.

Subjects were asked to refrain from using any medication or caffeine on the day of blood collection and to refrain from smoking for 4 h before collection time. For patients, the limb affected by CRPS was identified, and blood was drawn from the contralateral limb. Twenty-three of the patients were preparing to undergo therapeutic IV regional (Bier) block of the affected limb, as previously described (7). For control subjects, limb laterality for blood collection was determined by subject preference.

An IV catheter was started by using sterile technique in a distal vein of the chosen limb, usually in the dorsal venous arch of the hand or wrist. After confirmation of catheter placement by observation of blood return, an intermittent infusion cap was attached, and the catheter was flushed once with heparin sodium (100 U in 1 mL of solution) to maintain catheter patency.

Efforts were made to minimize the noxious or visual effects of stimuli related to blood collection that might artificially increase plasma catecholamine levels. To reduce the immediate effects of pain and anxiety surrounding the needlestick, each subject rested alone in the supine position in a quiet, dimly lit room for 30 min after IV insertion. The investigator then re-entered the room and asked each subject to remain supine, facing away from the IV site. The infusion lock was removed, and 3 mL of blood was withdrawn through the IV and discarded to minimize the risk of heparin contamination. A second syringe was used to draw an additional 10 mL of blood for analysis. Either the IV catheter was then maintained for access during the Bier block, or it was removed and a sterile dressing was applied.

The 10 mL of blood was immediately transferred into 2 sterile 5-mL vacuum collection tubes containing EDTA. The tubes were labeled with patient initials and the date of collection and were immediately transported on ice to a centrifuge, where plasma was separated, extracted, and stored at –70°C.

A subset of 18 CRPS patients completed standardized psychometric questionnaires before blood collection. Instruments included the Beck Depression Inventory (BDI) (16) and Beck Anxiety Inventory (BAI) (17), which are well validated measures of depression and anxiety states, respectively, and the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) (18), an extensively validated measure of personality functioning.

Frozen plasma samples were transported on dry ice to the MUSC chemistry laboratory for analysis. NE and E were extracted from plasma onto activated alumina and assayed with high-pressure liquid chromatography with electrochemical detection, with dihydroxybenzylamine as the internal standard. The sensitivity of the assay was 15 pg/mL for both compounds. NE levels were determined on all samples submitted for analysis. E levels were determined for 25 (83%) of 30 controls and for 30 (91%) of 33 patients.

All analyses were conducted with SPSS statistical software (SPSS Inc., Chicago, IL). Age matching between groups was tested with an independent-samples Student’s t-test. Sex matching was tested with nonparametric 2 x 2 {chi}2 analysis. Control ranges for plasma NE and E were calculated on the basis of the upper and lower limits of the 95% confidence interval for the control sample. Because NE values were normally distributed, control and patient plasma NE distributions were compared by using simple factorial analysis of variance. E values did not approach a normal distribution in either patients or controls; groups were therefore compared by using the nonparametric Mann-Whitney U-test.

Although the available sample size was small, we were able to conduct a preliminary test of the relationships between catecholamine levels and scores on the BDI, BAI, and MMPI-2. NE distribution was normal within the subset of CRPS patients who completed psychometric instruments, although the distribution of E was nonnormal. Therefore, correlations between the psychometric measures and NE levels were examined by using parametric correlations (Pearson’s r), whereas correlations with E levels were analyzed with nonparametric correlations (Spearman’s {rho}).

Fourteen (47%) of 30 CRPS patients and 14 (56%) of 25 controls had E concentrations less than the lower limit of detection of the assay, and these were coded as 0 for statistical analyses. Sample sizes for analyses of psychometric measures in this pilot study varied because of missing data (ranging from 12 for the BDI and BAI to 16 for the MMPI-2). The maximum number of subjects available for each variable was used in all analyses.

A priori directional hypotheses regarding relationships between depression/anxiety and catecholamines were tested by using one-tailed probability values to increase statistical power, given the limited sample size for these variables. Probability values for all other analyses were two tailed.


   Results
Top
 Abstract
 Introduction
 Methods
 Results
Discussion
 References
 
Group demographics are summarized in Table 1. Seventy-three percent of the CRPS patients and 50% of control subjects were female. The sex ratio across groups approached, but did not reach, statistical significance (Pearson {chi}2 = 3.442; P < 0.08). Age distributions across the two groups were not significantly different (P > 0.10). Within-group analyses indicated that mean age was not significantly different across sexes in either the CRPS or control groups (P > 0.10).


View this table:
[in this window]
[in a new window]
  		Table 1. Demographics for Complex Regional Pain Syndrome (CRPS) Patients and Control Subjects
 
The 95% confidence intervals for the control group were used to define "normal" catecholamine ranges. Results for NE are summarized in Table 2. Seventy-eight percent of CRPS patients had NE levels more than the upper limit (210 pg/mL) of the control range. The largest NE concentration seen in the CRPS group (932 pg/mL) was more than fourfold larger than this upper limit. Not surprisingly, analysis of variance demonstrated significantly larger NE concentrations for the patient group compared with controls (F1,57 = 14.82; P < 0.001), and this difference was not explained by between-group differences in age or sex distribution (analysis of covariance: F1,57 = 11.43; P < 0.001).


View this table:
[in this window]
[in a new window]
  		Table 2. Plasma Norepinephrine (NE) Levels in Complex Regional Pain Syndrome Patients and Controls
 
Results for E are summarized in Table 3. Fifty-two percent of CRPS patients had levels more than the upper limit (26 pg/mL) of the control range, and the highest patient E value (2370 pg/mL) was approximately 90 times the upper normal limit. Nonparametric analysis of E data indicated a trend for larger plasma E concentrations in the CRPS group than in controls; the difference approached, but did not reach, statistical significance (Mann-Whitney U-test, 259.0; P < 0.06). There was no significant correlation between plasma NE and E levels among CRPS patients (Spearman’s {rho} = 0.05;P > 0.10) or controls (Spearman’s {rho} = –0.04; P > 0.10).


View this table:
[in this window]
[in a new window]
  		Table 3. Plasma Epinephrine (E) Levels in Complex Regional Pain Syndrome Patients and Controls
 
Among CRPS patients, plasma NE was unrelated to sex, but men displayed significantly higher levels of E ({eta}27 = –0.41; P < 0.05). In contrast, there was a significant relationship between NE and sex among controls, with higher plasma NE levels in female patients ({eta}28 = 0.64; P < 0.001). Male controls displayed a trend toward higher E levels, but this did not reach statistical significance ({eta}23 = –0.38; P < 0.1). Grossly, no significant differences were found between men and women on any of the psychometric tests (P <0.1); however, this sample was too small to make any definitive statements as to sex/psychometric effects.

Age and E were significantly related in the control group, with higher E levels in younger individuals (Spearman {rho} 23 = –0.46; P < 0.05). In contrast, neither NE nor E was significantly correlated with age in the CRPS group (all correlations: P > 0.10).

Table 4 presents exploratory correlations between psychometric measures (BDI, BAI, and MMPI-2) and plasma E and NE levels for a subset of CRPS patients. Because correlations were not based on a specific directional hypothesis, P values are given strictly for descriptive reasons. Plasma NE was not significantly correlated with any of the psychometric scores. However, several significant relationships were observed between psychometric results and plasma E levels.


View this table:
[in this window]
[in a new window]
  		Table 4. Correlations Between Psychometric Measures and Plasma Catecholamine Levels
 
Despite the small sample size, a significant positive relationship was observed between plasma E and depression scores on the BDI. Similar significant positive relationships were noted between E levels and Scales 1, 3, and 6 on the MMPI-2. Scale 1 measures an individual’s tendency toward denial of good health and admission of a variety of somatic symptoms (somatic focus). Scale 3 reflects denial of psychological and emotional problems, discomfort in social situations, and a general denial of physical health (avoidance or denial/suppression as a coping style). Scale 6 reflects social sensitivity, suspiciousness, rigid opinions and attitudes, and ideas of reference. (This scale is sometimes called the paranoia subscale, but in the context of these findings, it may best be understood as reflecting a sensitive, suspicious, or hostile attitude toward the world.)

Given the small sample size available for this analysis, we considered the possibility that extreme cases could bias the results. However, exclusion of statistical outliers for both E and NE did not appreciably alter the pattern of significant relationships observed.


   Discussion
Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
References
 
Research has increased our understanding of the pathogenesis of neuropathic pain states, including CRPS. Histochemical studies in animal models suggest that catecholamines are involved in the pathophysiology of some types of neuropathic pain (10,19,20). Acute tissue injury is accompanied by the local release of multiple compounds, including neuropeptides (21), which ultimately sensitize peripheral afferent nerve endings (both nociceptors and nonnociceptive terminals) to usually innocuous stimuli. One mechanism for this sensitization is the upregulation of excitatory receptors, including NE receptors, at the terminals of injured nociceptive and nonnociceptive afferents (9,22). New axonal sprouts from injured afferents develop abnormal, painful sensitivity to both NE (23) and E (24,25). This hypersensitivity to catecholamines can develop in the absence of postganglionic sympathetic input (8) and may be the result of catecholaminergic receptor upregulation (26). Sensitized nerve terminals may produce spontaneous discharges even in the absence of external stimulation (27). Taken together, these findings suggest that exposure of injured tissue to circulating NE and E may contribute to the spontaneous pain and allodynia of CRPS.

The original theoretical concept of reflex sympathetic dystrophy (also known as CRPS) implicated sympathetic nervous hyperactivity in the affected limb as the mechanism driving the syndrome. However, current research indicates that regional venous plasma NE (and, indirectly, sympathetic function) may be decreased in the affected limb relative to the contralateral unaffected limb (6,7). If tissue injury sensitizes peripheral nociceptors to catecholamines, then the pain and dysautonomic phenomena seen in CRPS could be caused by normal (or high) systemic levels of catecholamines affecting supersensitive tissue, rather than by high regional levels of catecholamines produced by an overactive sympathetic system (6,7). Indeed, the decrease in NE seen in CRPS patients may actually reflect local sympathetic hypofunction that is perhaps related to damage to sympathetic efferents (7), and this is consistent with the clinical observation that many patients go through a period of apparent sympathetic hypofunction acutely (hot, red, and dry) before developing the characteristic chronic presentation (cold, blue, and sweaty) (7).

Although the sympathetic nervous system efferents may not be overdriven in CRPS, experimental evidence does suggest functional sympathetic/sensory coupling at the dorsal root ganglion (DRG) in animal models of neuropathic pain. The nociceptive barrage of pain signals from sensitized afferent terminals induces windup of wide dynamic range neurons in the DRG, manifested by increased firing frequency and decreased discrimination between noxious and normally innocuous stimuli (28). Postganglionic sympathetic activation has been shown to potentiate ectopic discharges from primary DRG neurons during windup (29). This relationship may have a structural basis; sympathetic postganglionic axons form basket-like skeins around the somata of DRG sensory neurons in animal and human neuropathic pain states (30). There are thus sound arguments for both peripheral noradrenergic sensitization (8,9) and for direct sympathetic nervous involvement (31) in the maintenance of neuropathic pain states. Both mechanisms may be involved in CRPS to varying degrees.

In this pilot study we found that levels of circulating NE were higher than normal control levels in 78% of our CRPS sample, a statistically significant difference. If CRPS patients are regionally sensitized to NE at the tissue level and if upregulation of peripheral NE receptors is tied to abnormal nociception and vasomotor function, then increased circulating NE levels would have marked clinical significance. Patients with high plasma NE would be expected to experience greater regional pain and manifest increased edema, vasoconstriction, and other hyperadrenergic manifestations of CRPS. Subsequent investigations should assess these variables and correlate them with NE levels.

This finding raises questions about the clinical distinction between SMP and SIP (4,32). Patients with SMP respond to sympatholytic therapies, whereas SIP patients do not. This difference in response could reflect differing regional or circulating NE levels, differing tissue sensitivities to NE, or both. All CRPS patients involved in this study had documented SMP. Further research comparing SMP and SIP patients and the relationship of these subsets of CRPS to catecholamine levels, clinical presentation, and psychometric testing is indicated.

We found levels of circulating E to be higher than normal control values in 52% of CRPS patients, with concentrations up to 90 times larger than normal in one patient. (None of the individuals with increased E levels had known pheochromocytomas or other endocrine, gastrointestinal (GI), or kidney pathology, nor were any found on subsequent workup.) However, the difference in plasma E levels between groups was not statistically significant. Whether the marked E increases in certain individuals reflect preexisting emotional distress, anxiety over the sampling technique, some other premorbid or comorbid hyperadrenergic state, or another process entirely (such as an artifact) is unexplained. One source of variance not controlled for in this pilot study was the fact that some of the subjects were taking antidepressant drugs for pain or depression, and these drugs theoretically may influence blood catecholamine levels. This factor should be considered in a definitive trial.

One might hypothesize that increased E and NE levels in CRPS are a consequence of the pain and distress that accompany the syndrome, rather than a manifestation of endocrine pathology or an autonomic or psychological state peculiar to CRPS. For this hypothesis to be correct, chronic pain patients as a group would be expected to have increased catecholamine levels. A review of the literature fails to support this hypothesis. NE and E levels are similar to control values in patients with fibromyalgia (32,33), painful diabetic neuropathy (34), and cluster headaches (35). Plasma NE was less than control levels in patients with migraine (36), and concentrations of NE, E, and dopamine were decreased in patients with tension-type headaches (37). The only studied pain states besides CRPS that were accompanied by increases of plasma NE and E were acute pain conditions, i.e., venipuncture (34) and early myocardial infarction (38,39). Please note our efforts to minimize the acute effect of venipuncture, in the Methods section.

As noted, one possible reason for plasma NE and E increases is affective distress. The mechanisms underlying this relationship include both central activation of the sympathetic nervous system (primarily accounting for systemic NE) and pituitary/adrenal activation (primarily accounting for E). Several studies suggest that CRPS patients may have more emotional distress than patients with other types of chronic pain conditions (15,40–45), but they also may experience "more" pain. Of course, there is no way to compare absolute pain levels across diagnoses.

Anxiety, stress, and pain all increase circulating catecholamine levels (34,46–48). In our small sample, we found that plasma E was positively correlated with scores on psychometric measures that reflected depression, high somatic focus, avoidant coping style, and emotional sensitivity/suspiciousness ("paranoia/hostility"). Our findings support the hypothesis that psychological distress and increased plasma catecholamines are related in CRPS patients (41,49–51), although no causal connection with CRPS development can be assumed, given the correlational nature of these data and the small sample size. We did not correlate pain severity with depression, anxiety, or E levels, and these relationships should be explored carefully in future investigations.

The kidneys and GI tract are also significant sources of peripheral circulating NE and E. The differential contribution of various organs to circulating NE and E was not addressed in this pilot investigation.

By contrast, no significant correlations were demonstrated between NE levels and psychometric scores, and the concentration of one measured catecholamine did not predict that of the other. These were unexpected findings; one possible explanation is separate roles for E and NE in the development or maintenance of CRPS. Whereas NE has been experimentally linked to peripheral sensitization, allodynia, and hyperalgesia, E may be more involved in the realm of emotional distress and the stress response to pain. Further investigation is necessary to clarify these relationships.

Do increased E and NE levels predispose individuals to develop CRPS (52)? Our data provide no ready answers. Whether increased NE and E predate the development of CRPS is unknown. No published studies have documented psychological status and catecholamine levels before the onset of the syndrome. Whatever the ultimate cause of CRPS, our findings are consistent with the theoretical effects of many of the treatments recommended for the syndrome (53). Early and aggressive treatment of stress, anxiety, and depression by methods such as relaxation training (14) may reduce plasma NE and E levels, theoretically decreasing peripheral sensitization and pain and thereby alleviating emotional distress. Pharmacologic management of pain, depression, and anxiety may also help to reduce affective distress, the adrenergic stress response, and circulating catecholamine levels, leading to further beneficial effects.

The connection between plasma catecholamines, psychological state, and CRPS certainly deserves exploration beyond this pilot study. A group of patients with SIP should be studied and compared with SMP patients to examine any differences in plasma catecholamine levels or psychometric scores. Enlargement of sample size, expansion of the psychometric battery, and use of a control group (perhaps one with a different chronic pain condition) will increase the statistical power and robustness of the study. We did not control for the duration of CRPS symptoms, time since the last sympathetic block (except that there was at least one week since the last block), type of block, comorbid medical conditions, or the roles of any long-acting medications taken by the patients on the days before sampling. These variables must be considered in further investigations.

Even as we understand more about the complex pathophysiology of neuropathic pain, many aspects of CRPS remain a mystery, and each new piece of knowledge tends to raise more questions. The exact role of catecholamines in the genesis and maintenance of CRPS is still incompletely understood. In this study, CRPS patients with SMP demonstrated increases in plasma NE and (to a lesser extent) E compared with normal control subjects, and increased E was correlated with psychometric scores that indicated affective distress and certain personality characteristics. Whether these psychological characteristics originated before or after the onset of CRPS remains unclear. Further investigation may lead us toward techniques for the identification of individuals at high risk for CRPS and may eventually lead to effective preventive measures and more effective treatments.


   Acknowledgments
 
The Ralph and Marian C. Falk Trust Fund provided partial funding for this investigation.

The authors gratefully acknowledge the support and assistance of the following individuals: Felice Borisy Rudin, PhD, for critical review of the manuscript; and John Cate for the use of the MUSC laboratory facilities.


   References
Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 

  1. Merskey H, Bogduk N. Complex regional pain syndrome, type I (reflex sympathetic dystrophy). In: Merskey H, Bogduk N, eds. Classification of chronic pain. Seattle: IASP Press, 1994: 40–43.
  2. Abrams S. Incidence-hypothesis-epidemiology. In: Stanton-Hicks M, ed. Pain and the sympathetic nervous system. Boston: Kluwer Academic Publishers, 1990: 1–15.
  3. Wang K, Kenneth AJ, Ilstrup DM. Sympathetic blocks for reflex sympathetic dystrophy. Pain 1985; 23: 13–7.[Web of Science][Medline]
  4. Raja SN, Treede D, Davis KD, Campbell JN. Systemic alpha-adrenergic blockade with phentolamine: a diagnostic test for sympathetically maintained pain. Anesthesiology 1991; 74: 691–8.[Web of Science][Medline]
  5. Manning DC. Reflex sympathetic dystrophy, sympathetically maintained pain, and complex regional pain syndrome: diagnoses of inclusion, exclusion, or confusion? J Hand Ther 2000; 13: 260–8.[Medline]
  6. Drummond PD, Finch PM, Smythe GA. Reflex sympathetic dystrophy: the significance of differing plasma catecholamine concentrations in affected and unaffected limbs. Brain 1991; 114: 2025–36.[Abstract/Free Full Text]
  7. Harden RN, Duc TA, Williams TR, et al. Norepinephrine and epinephrine levels in affected versus unaffected limbs in sympathetically maintained pain. Clin J Pain 1994; 10: 324–30.[Web of Science][Medline]
  8. Rubin G, Kaspi T, Rappaport ZH, et al. Adrenosensitivity of injured afferent neurons does not require the presence of postganglionic sympathetic terminals. Pain 1997; 72: 183–91.[Web of Science][Medline]
  9. Sato J, Perl ER. Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. Science 1991; 251: 1608–10.[Abstract/Free Full Text]
  10. Perl ER. Causalgia, pathological pain, and adrenergic receptors. Proc Natl Acad Sci U S A 1999; 96: 7664–7.[Abstract/Free Full Text]
  11. Drummond PD, Finch PM, Skipworth S, Blockey P. Pain increases during sympathetic arousal in patients with complex regional pain syndrome. Neurology 2001; 57: 1296–303.[Abstract/Free Full Text]
  12. Charney DS, Woods SW, Nagy LM. Noradrenergic function in panic disorder. J Clin Psychiatry 1990; 51: 5–10.
  13. Light KC, Kothandapani RV, Allen MT. Enhanced cardiovascular and catecholamine responses in women with depressive symptoms. Int J Psychophysiol 1998; 28: 157–66.[Web of Science][Medline]
  14. Infante JR, Torres-Avisbal M, Pinel P, et al. Catecholamine levels in practitioners of the transcendental meditation technique. Physiol Behav 2001; 72: 141–6.[Medline]
  15. Bruehl S, Husfeldt B, Lubenow T, et al. Psychological differences between reflex sympathetic dystrophy and non-RSD chronic pain patients. Pain 1996; 67: 107–14.[Web of Science][Medline]
  16. Beck A, Steer RA. Manual for the Beck Depression Inventory. San Antonio, TX: The Psychological Corporation, 1987.
  17. Beck AT, Epstein N, Brown G, Steer RA. An inventory measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893–7.[Web of Science][Medline]
  18. Hathaway SR, McKinnley JC. Minnesota Multiphasic Personality Inventory-2. Minneapolis: University of Minnesota Press, 1989.
  19. Moon DE, Lee DH, Han HC, et al. Adrenergic sensitivity of the sensory receptors modulating mechanical allodynia in a rat neuropathic pain model. Pain 1999; 80: 589–95.[Web of Science][Medline]
  20. Shir Y, Seltzer Z. Effects of sympathectomy in a model of causalgiform pain produced by partial sciatic nerve injury in rats. Pain 1991; 45: 309–20.[Web of Science][Medline]
  21. Birklein F, Schmelz M, Schifter S, Weber M. The important role of neuropeptides in complex regional pain syndrome. Neurology 2001; 57: 2179–84.[Abstract/Free Full Text]
  22. Janig W. The sympathetic nervous system in pain: physiology and pathophysiology. In: Stanton-Hicks M, ed. Pain and the sympathetic nervous system. Boston: Kluwer Academic Publishers, 1990: 17–89.
  23. Chemali KR, Gorodeski R, Chelimsky TC. Alpha-adrenergic supersensitivity of the sudomotor nerve in complex regional pain syndrome. Ann Neurol 2001; 49: 453–59.[Web of Science][Medline]
  24. Chabal C, Jacobson L, Russell LC, Burchiel KJ. Pain response to perineuronal injection of normal saline, epinephrine and lidocaine in humans. Pain 1992; 49: 9–12.[Web of Science][Medline]
  25. Scadding JW. Development of ongoing activity, mechanosensitivity, and adrenaline sensitivity in severed peripheral nerve axons. Exp Neurol 1981; 73: 354–64.
  26. Kurvers H, Daemen M, Slaaf D, et al. Partial peripheral neuropathy and denervation induced adrenoceptor supersensitivity: functional studies in an experimental model. Acta Orthop Belg 1998; 64: 64–70.
  27. Woolf CJ, Mannion RJ. Neuropathic pain; aetiology, symptoms, mechanisms, and management. Lancet 1999; 353: 1959–64.[Web of Science][Medline]
  28. Roberts W. A hypothesis on the physiological basis for causalgia and related pains. Pain 1986; 24: 297–311.[Web of Science][Medline]
  29. Devor M. Modulation of activity in dorsal root ganglion neurons by sympathetic activation in nerve-injured rats. J Neurophysiol 1994; 71: 38–47.[Abstract/Free Full Text]
  30. Shinder V, Govrin-Lippman R, Cohen S, et al. Structural basis of sympathetic-sensory coupling in rat and human dorsal root ganglia following peripheral nerve injury. J Neurocytol 1999; 28: 743–61.[Web of Science][Medline]
  31. Levine JD, Taiwo YO, Collins SD, Tam JK. Noradrenaline hyperalgesia is mediated through interaction with sympathetic postganglionic neuron terminals rather than activation of primary afferent nociceptors. Nature 1986; 323: 158–60.[Medline]
  32. Wilson PR. Sympathetically maintained pain: diagnosis, measurement and efficacy of treatment. In: Stanton-Hicks M, ed. Pain and the sympathetic nervous system. Boston: Kluwer Academic Publishers, 1990: 113–24.
  33. Yunus MB, Dailey JW, Aldag JC, et al. Plasma and urinary catecholamines in fibromyalgia: a controlled study. J Rheumatol 1992; 19: 95–7.[Web of Science][Medline]
  34. Tsigos C, Reed P, Weinkove CY, et al. Plasma norepinephrine in sensory diabetic polyneuropathy. Diabetes Care 1993; 16: 722–7.[Abstract]
  35. Figuerola ML, Levin G, Leston JA, Barontini MB. Sympathetic adrenomedullary activity in cluster headache. Funct Neurol 1992; 7: 109–13.[Medline]
  36. Martinez F, Castillo J, Pardo J, et al. Catecholamine levels in plasma and CSF in migraine. J Neurol Neurosurg Psychiatry 1993; 56: 1119–21.[Abstract/Free Full Text]
  37. Castillo J, Martinez F, Leira R. Plasma monoamines in tension-type headache. Headache 1994; 34: 531–5.[Web of Science][Medline]
  38. Husebye E, Kjeldsen SE, Lande K, et al. Increased arterial adrenaline is related to pain in uncomplicated myocardial infarction. J Intern Med 1990; 228: 617–22.[Web of Science][Medline]
  39. Schomig A. Catecholamines in myocardial ischemia: systemic and cardiac release. Circulation 1990; 82: 113–22.
  40. Bonica JJ. Causalgia and other reflex sympathetic dystrophies. In: Bonica JJ, ed. Management of pain. Philadelphia: Lea & Febiger, 1990: 220–43.
  41. Bruehl S, Carlson CR. Predisposing psychological factors in the development of reflex sympathetic dystrophy. Clin J Pain 1992; 8: 287–99.[Web of Science][Medline]
  42. Ciccone DS, Bandilla EB, Wu W. Psychological dysfunction in patients with reflex sympathetic dystrophy. Pain 1997; 71: 323–33.[Web of Science][Medline]
  43. Geertsen JHB, de Bruijn H, de Bruijn-Kofman AT, Arendzen JH. Reflex sympathetic dystrophy: early treatment and psychological aspects. Arch Phys Med Rehabil 1994; 75: 442–6.[Web of Science][Medline]
  44. Geertsen JHB, de Bruijn-Kofman AT, de Bruijn HP. Stressful life events and psychological dysfunction in complex regional pain syndrome type I. Clin J Pain 1998; 14: 143–7.[Web of Science][Medline]
  45. Hardy MA, Merritt WH. Psychological evaluation and pain assessment in patients with reflex sympathetic dystrophy. J Hand Ther 1988; 7: 155–64.
  46. Abelson JL, Glitz D, Cameron OG, et al. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 1991; 48: 157–62.[Abstract/Free Full Text]
  47. Contrada RJ, Krantz DS. Stress, reactivity and type A behavior: current status and future directions. Ann Behav Med 1988; 10: 64–70.
  48. Hajos M, Svensson K, Nissbrandt H, et al. Effects of capsaicin on central monoaminergic mechanisms in the rat. J Clin Hypertens 1987; 3: 727–42.[Web of Science][Medline]
  49. Pak TJ, Martin GM, Magnes JL, Kavanaugh GJ. Reflex sympathetic dystrophy: review of 140 cases. Minn Med 1970; 53: 507–12.[Medline]
  50. Horowitz LH. Iatrogenic causalgia: classification, clinical findings, and legal implications. Arch Neurol 1984; 41: 821–4.[Abstract/Free Full Text]
  51. Van Houdenhove B. Neuro-algodystrophy: a psychiatrist’s view. Clin Rheumatol 1986; 5: 399–406.[Web of Science][Medline]
  52. Ecker A. Norepinephrine in reflex sympathetic dystrophy: an hypothesis. Clin J Pain 1989; 5: 313–5.[Web of Science][Medline]
  53. Sanders SH, Harden RN, Benson SE, Vicente PJ. Clinical practice guidelines for chronic non-malignant pain syndrome patients. II. An evidence-based approach. J Back Musculoskel Rehabil 1999; 13: 47–58.
Accepted for publication April 27, 2004.




This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
F. Wesseldijk, D. Fekkes, F. J. Huygen, E. Bogaerts-Taal, and F. J. Zijlstra
Increased Plasma Serotonin in Complex Regional Pain Syndrome Type 1
Anesth. Analg., June 1, 2008; 106(6): 1862 - 1867.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harden, R. N.
Right arrow Articles by Gracely, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harden, R. N.
Right arrow Articles by Gracely, R. H.
Related Collections
Right arrow Pain
Right arrow Pharmacology

Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins and Stanford University Libraries' HighWire Press®. Copyright 2004 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press